deferoxamine has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 7.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 3.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vlahakos, D | 1 |
| Arkadopoulos, N | 1 |
| Kostopanagiotou, G | 1 |
| Siasiakou, S | 1 |
| Kaklamanis, L | 1 |
| Degiannis, D | 1 |
| Demonakou, M | 1 |
| Smyrniotis, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for deferoxamine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi | 2012 |